Ali-Jackson Kamil 4
Research Summary
AI-generated summary
Rigel Pharmaceuticals (RIGL) Director Kamil Ali-Jackson Sells 2,500 Shares
What Happened
Kamil Ali-Jackson, a director of Rigel Pharmaceuticals (RIGL), sold 2,500 shares on June 22, 2026 at $35.00 per share, generating $87,500 in proceeds. The sale was effected under a 10b5-1 trading plan and was executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), not as an investment sale.
Key Details
- Transaction date and price: 2026-06-22 — 2,500 shares at $35.00 each (total $87,500).
- Shares owned after transaction: Not disclosed in this filing.
- Footnotes: (1) Sale was made pursuant to a 10b5-1 plan adopted November 7, 2025. (2) Shares were sold to cover tax withholding from RSU vesting and were not sold for investment purposes.
- Filing timeliness: Form 4 filed on 2026-06-24 (timely within the standard reporting window).
Context
Sales executed under 10b5-1 plans and those to cover tax withholding are common and typically routine; they do not necessarily signal a change in an insider’s view of the company. For retail investors, purchases are generally more informative than routine sales, but this disclosure is useful for tracking insider activity and share turnover.